PCSK9 Inhibitors

Alirocumab - Bococizumab - Evolocumab      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

cardiovascular prevention

alirocumab
ODYSSEY OPTIONS I   alirocumabezetimibe (on top statin)negative
ODYSSEY OPTIONS II   alirocumabezetimibe (on top statin)negative
ODYSSEY MONO      NCTalirocumabezetimibe aloneLow risk of bias negative
ODYSSEY Long-Term, 2015      NCTalirocumabplacebo (on top statins)Exploratory suggesting
ODYSSEY Alternative      NCTalirocumabplacebo (on top statins)Low risk of bias negative
ODYSSEY OUTCOMES, 2018      NCTalirocumabplacebo (on top statins)Low risk of bias conclusive
ODYSSEY FH 1      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY FH 2      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY HIGH FH      NCTalirocumabplacebo (on top statins)negative
ODYSSEY COMBO        NCTalirocumabplacebo (on top statins)Low risk of bias negative
ODYSSEY COMBO II        NCTalirocumabplacebo (on top statins)Low risk of bias negative
evolocumab
MENDEl 2    NCTevolocumab -
Mendel 1, 2012      NCTevolocumab -
YUKAWA-1, 2014   evolocumab -
GAUSS 2    NCTevolocumabezetimibe alonenegative
GAUSS 1, 2012    NCTevolocumabplacebonegative
DESCARTES, 2014    NCTevolocumabplacebo (on top statins)negative
LAPLACE-TIMI 57    NCTevolocumabplacebo (on top statins) -
RUTHERFORD-1    NCTevolocumabplacebo (on top statins)negative
LAPLACE 2, 2014    NCTevolocumabplacebo (on top statins)negative
RUTHERFORD-2, 2015    NCTevolocumabplacebo (on top statins)negative
FOURIER, 2017      NCTevolocumabplacebo (on top statins)Low risk of bias conclusive